Sagimet Doses First Patient in Phase 3 U.S. Acne Trial, Targets Results in Late 2027
Key Points
- Sagimet Biosciences has dosed the first patient in AURORA, its pivotal U.S. Phase 3 trial of denifanstat for moderate to severe acne.
- The study plans to enroll approximately 800 patients, including 450 adolescents aged 12–17.
- Patients will receive denifanstat 50 mg or placebo once daily for 12 weeks, with an additional 40-week safety study available to eligible participants.
- Topline results are expected in the second half of 2027.
- The trial could support a U.S. approval application, but denifanstat remains investigational.
Sagimet Biosciences (NASDAQ: SGMT) has begun treating patients in AURORA, moving its experimental once-daily acne pill into a pivotal U.S. study.
The trial builds on positive Phase 3 findings from China, where licensing partner Ascletis is developing denifanstat as ASC40. Those results support further testing but do not guarantee success in the U.S. program.
U.S. Trial Will Measure Skin Clearance and Lesion Reductions
AURORA will randomly assign approximately 800 patients aged 12 and older to denifanstat or placebo, with twice as many receiving the active treatment.
At week 12, researchers will assess three main outcomes:
- The proportion achieving clear or almost-clear skin with at least a two-point improvement on a global assessment scale.
- Changes in inflammatory acne lesion counts.
- Changes in non-inflammatory acne lesion counts.
Approximately 530 patients who complete the initial treatment period may enter a further 40-week study evaluating long-term safety. That extension will be open-label, meaning treatment will be known.
Denifanstat Targets Oil Production and Inflammation
Denifanstat blocks fatty acid synthase, or FASN, an enzyme involved in fat production. Sagimet is developing it to address sebum—the skin’s oil—and inflammation, two drivers of acne.
According to the company, Ascletis’ 12-week Phase 3 trial met all primary and secondary endpoints. Its open-label extension also reported continued improvements through 52 weeks.
The extension provides longer-term treatment experience, but it does not offer the same placebo-controlled comparison as the initial study.
Investor Takeaway: Trial Execution and 2027 Results Are the Next Tests
For SGMT investors, first-patient dosing marks progress from trial preparation to active treatment. Sagimet expects topline results in the second half of 2027 and intends the study to support a potential FDA application.
The key questions are whether AURORA meets its efficacy goals and establishes an acceptable safety profile, including in adolescents. The announcement does not provide an FDA filing date or guarantee approval.
